ライフサイエンスコーパス: pandemic influenza

1 jor threat to human health and the source of pandemic influenza.

2 to reduce the impact of epidemic as well as pandemic influenza.

3 he public health burden of both seasonal and pandemic influenza.

4 can have dramatic effects on transmission of pandemic influenza.

5 that can shed light on the latent period of pandemic influenza.

6 tiviral drug treatment during an outbreak of pandemic influenza.

7 morbidity and mortality during seasonal and pandemic influenza.

8 es vulnerable to a third, wintertime wave of pandemic influenza.

9 icant epidemiological impact on seasonal and pandemic influenza.

10 provide a rapid response platform to control pandemic influenza.

11 ates had been associated with confirmed 2009 pandemic influenza A (H1N1) [2009 H1N1] virus infection.

12 respond to the first and subsequent years of pandemic influenza A (H1N1) circulation.

13 The 2009 pandemic influenza A (H1N1) has been recognized to cause

14 for morbidity and mortality related to 2009 pandemic influenza A (H1N1) infection.

15 Since the introduction of pandemic influenza A (H1N1) to the USA in 2009, the Infl

16 ated in Maine before or concurrent with 2009 pandemic influenza A (H1N1) virus (pH1N1) peak activity.

17 , an outbreak due to infection with the 2009 pandemic influenza A (H1N1) virus (pH1N1) was investigat

18 spiratory viral panel (RVP) results for 2009 pandemic influenza A (H1N1) virus specimens.

19 osition 222 in the hemagglutinin of the 2009 pandemic influenza A (H1N1) virus was developed.

20 nosuppressed patients infected with the 2009 pandemic influenza A (H1N1) virus within a few days afte

21 re prominent features of infection with 2009 pandemic influenza A (H1N1) virus.

22 Oseltamivir resistance among 2009 pandemic influenza A (H1N1) viruses (pH1N1) is rare.

23 yped for seasonal A/H1, A/H3, A/H5, and 2009 pandemic influenza A (pH1N1).

24 Following detection of pandemic influenza A H1N1 (pH1N1) in Dallas/Fort Worth,

25 Molecular evolutionary analyses of the 2009 pandemic influenza A H1N1 [A(H1N1)pdm09] virus revealed

26 cation among hospitalized patients with 2009 pandemic influenza A H1N1 [pH1N1] in the United States i

27 Even though the majority of cases of 2009 pandemic influenza A H1N1 are mild, severe disease does

28 he role of seasonal influenza vaccination in pandemic influenza A H1N1 disease is important to addres

29 The majority of cases of 2009 pandemic influenza A H1N1 in children have been mild.

30 ical presentations, and outcomes of the 2009 pandemic influenza A H1N1 in children.

31 All paediatric deaths related to pandemic influenza A H1N1 infection from June 26, 2009,

32 itted for at least 12 hr with a diagnosis of pandemic influenza A H1N1 infection in a single hospital

33 Clinical and epidemiological data of pandemic influenza A H1N1 infection in solid-organ trans

34 disease mortality rates associated with 2009 pandemic influenza A H1N1 infection with the ratio of ex

35 rs) have been disproportionately affected by pandemic influenza A H1N1 infection.

36 ory mortality rates associated with the 2009 pandemic influenza A H1N1 strain by age (0-17 years, 18-

37 from, and incidence of infection with, 2009 pandemic influenza A H1N1 virus is essential for modelli

38 ovascular mortality associated with the 2009 pandemic influenza A H1N1 was 15 times higher than repor

39 ascular mortality rates associated with 2009 pandemic influenza A H1N1 were multiplied by age to calc

40 boratory-confirmed deaths caused by the 2009 pandemic influenza A H1N1 were reported worldwide for th

41 70 paediatric deaths related to pandemic influenza A H1N1 were reported.

42 infected with novel viruses such as the 2009 pandemic influenza A H1N1, avian influenza A H5N1 virus

43 deaths (46,000-179,900) associated with 2009 pandemic influenza A H1N1.

44 ue number of the deaths associated with 2009 pandemic influenza A H1N1.

45 tality in patients admitted to hospital with pandemic influenza A H1N1pdm09 virus infection.

46 laboratory confirmed or clinically diagnosed pandemic influenza A H1N1pdm09 virus infection.

47 ships in ferrets infected with the 2009 H1N1 pandemic influenza A virus (H1N1pdm virus).

48 Seasonal and pandemic influenza A virus (IAV) continues to be a publi

49 /H1N1/pdm09) was first identified as a novel pandemic influenza A virus (IAV) in 2009.

50 rs to devise host-targeted therapies against pandemic influenza A virus (IAV) led us to investigate t

51 ng, and geographical origin of the 1918-1920 pandemic influenza A virus have remained tenaciously obs

52 To understand 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) c

53 Following the emergence of 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) i

54 We documented the introduction of 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) i

55 The emergence of swine-origin 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) p

56 circulating influenza A virus subtype; 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) r

57 de vaccination against infection due to 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) t

58 e induced by the monovalent inactivated 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) v

59 The 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) w

60 positive for influenza virus, including 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09; n

61 ealthy pregnant women and cultured with 2009 pandemic influenza A virus subtype H1N1 (H1N1/09).

62 increased risk for serious outcomes of 2009 pandemic influenza A virus subtype H1N1 (influenza A[H1N

63 ata about respiratory coinfections with 2009 pandemic influenza A virus subtype H1N1 during the 2009-

64 A virus subtype H3N2 predominated, and 2009 pandemic influenza A virus subtype H1N1 had little impac

65 In 2009, pandemic influenza A virus subtype H1N1 was detected in

66 ntly, mortality has emerged as an outcome of pandemic influenza A virus subtype H1N1, necessitating d

67 ality, of which 9 studied patients with 2009 pandemic influenza A virus subtype H1N1.

68 The risk of emerging pandemic influenza A viruses (IAVs) that approach the de

69 Pandemic influenza A viruses can emerge from swine, an i

70 ds represent a vast reservoir from which new pandemic influenza A viruses can emerge(1).

71 The emergence of new pandemic influenza A viruses requires overcoming barrier

72 a mixing vessel for the generation of novel pandemic influenza A viruses through reassortment becaus

73 There were 23 cases of confirmed 2009 pandemic influenza A(H1N1) (A[H1N1]pdm09) infection for

74 The 2009 pandemic influenza A(H1N1) (A[H1N1]pdm09) vaccine compon

75 asonal influenza (during 2003-2009) and 2009 pandemic influenza A(H1N1) (during 2009-2010).

76 d with seasonal influenza (n = 5270) or 2009 pandemic influenza A(H1N1) (H1N1pdm09; n = 4962).

77 eexisting antibodies to the hemagglutinin of pandemic influenza A(H1N1) 2009 (hereafter pandemic H1N1

78 person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus that occurred in a

79 eceptor-binding site of the hemagglutinin of pandemic influenza A(H1N1) 2009 viruses have been detect

80 After 2009, pandemic influenza A(H1N1) [A(H1N1)pdm09] cocirculated w

81 onfidence interval [CI], 2.61-6.13) for 2009 pandemic influenza A(H1N1) and 1.76 (95% CI, 1.33-2.32)

82 Seasonal TIV prevented pandemic influenza A(H1N1) and influenza B infections in

83 of 2009 may have triggered the fall wave of pandemic influenza A(H1N1) in the United States.

84 who received TIV also a had reduced risk of pandemic influenza A(H1N1) indicated by serology, with a

85 a from 683 critically ill patients with 2009 pandemic influenza A(H1N1) infection admitted to 35 inte

86 918 influenza pandemic and up to 34% of 2009 pandemic influenza A(H1N1) infections managed in intensi

87 seasonal influenza vaccination against 2009 pandemic influenza A(H1N1) remains unclear.

88 emic resurgence of influenza due to the 2009 pandemic influenza A(H1N1) strain (A[H1N1]pdm09) during

89 Three donor ferrets infected with 2009 pandemic influenza A(H1N1) underwent daily quantitative

90 lpha-secreting CD8(+)CD69(+) T cells to 2009 pandemic influenza A(H1N1) upon vaccination in the 2010-

91 To evaluate whether pandemic influenza A(H1N1) vaccination in pregnancy incr

92 ects, HI antibody responses against the 2009 pandemic influenza A(H1N1) vaccine strain were significa

93 nctional antibody responses against the 2009 pandemic influenza A(H1N1) vaccine strain.

94 All donors had ADCC responses against 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09) and avia

95 s infection, including coinfection with 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09) and infl

96 s season was characterized by a delayed 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09) epidemic

97 3N2) virus infection (P = .002) but not 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09) or influ

98 nfluenza season, nearly all circulating 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09) strains

99 ring the 2013-2014 influenza season was 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09).

100 he 2013-2014 influenza season, in which 2009 pandemic influenza A(H1N1) virus (influenza A[H1N1]pdm09

101 The admantane-resistant 2009 pandemic influenza A(H1N1) virus can develop the H275Y c

102 unit vaccine (ISV) targeting monovalent 2009 pandemic influenza A(H1N1) virus or live-attenuated infl

103 (H5N1) strain but comparable to that of 2009 pandemic influenza A(H1N1), based on the clinical signs,

104 Among patients with 2009 pandemic influenza A(H1N1), ratios for hIVIG (n = 9) ver

105 3N2) variant containing the M gene from 2009 pandemic influenza A(H1N1), termed "A(H3N2)vpM," to the

106 amma-secreting CD4(+)CD69(+) T cells to 2009 pandemic influenza A(H1N1).

107 intervals for influenza A(H3N2) (2.2 days), pandemic influenza A(H1N1)pdm09 (2.8 days), respiratory

108 e of patients acutely infected with the 2009 pandemic influenza A(H1N1)pdm09 virus (A[H1N1]pdm09) was

109 ly this method to a school-based outbreak of pandemic influenza A(H1N1)v that occurred in London, Uni

110 Low-dose priming with a mismatched pandemic influenza A(H5N1) vaccine would improve the rap

111 2009 pandemic influenza A/H1N1 (A(H1N1)pdm09) was first detec

112 re frequently in patients infected with 2009 pandemic influenza A/H1N1 strain (versus seasonal strain

113 epithelial cell cultures were infected with pandemic influenza A/H1N1 virus in vitro.

114 A small proportion (1%-1.5%) of 2009 pandemic influenza A/H1N1 virus strains (A[H1N1]pdm09) a

115 asonal influenza A/Panama/2007/99 (H3N2) and pandemic influenza A/Netherlands/602/2009 (H1N1) viruses

116 sociated with an increased risk (RR for 2009 pandemic influenza A[H1N1] virus, 5.3 [95% CI, 3.2-8.7];

117 Through annual epidemics and global pandemics, influenza A viruses (IAVs) remain a significa

118 ommunity burden and severity of seasonal and pandemic influenza across different age groups and study

119 which corresponded to the timing of highest pandemic influenza activity.

120 ation was associated with protection against pandemic influenza and a reduction in hospital admission

121 lay in facilitating the geographic spread of pandemic influenza and highlight the need for further in

122 ped our understanding of the epidemiology of pandemic influenza and informs analysis of current and f

123 blic health practitioners commonly ask about pandemic influenza and match these with analytical metho

124 strain could also be useful in epidemic and pandemic influenza and should be considered for influenz

125 rovide reliable surveillance for seasonal or pandemic influenza and should be interpreted with cautio

126 onsidered a requirement for the emergence of pandemic influenza, and advanced knowledge of the molecu

127 , was antigenically similar to the 1918 H1N1 pandemic influenza, and consequently was considered to b

128 nt seasonal vaccines are ineffective against pandemic influenza, and production of a vaccine matched

129 Seasonal and pandemic influenza are significant public health concern

130 pulation size changes, seasonal factors, and pandemic influenza, as appropriate.

131 ize the timing and intensity of seasonal and pandemic influenza at the national (United States), regi

132 Control of pandemic influenza by social-distancing measures, such a

133 The first pandemic influenza case detected by USAMRU-K surveillanc

134 e first wave and starting the second wave of pandemic influenza cases.

135 erved birth depressions were consistent with pandemic influenza causing first trimester miscarriages

136 ntibody against swine influenza A/H1N1(2009) pandemic influenza, children received 1 dose of 2010/201

137 za vaccine that could diminish the threat of pandemic influenza disease and generally reduce the sign

138 Apart from the period of pandemic influenza due to influenza A virus subtype H1N1

139 to be demonstrated and, indeed, outbreaks of pandemic influenza during more humid spring, summer, and

140 Additionally, B cell responses to pandemic influenza H1N1 vaccination and infection in dif

141 des protection against the 2009 swine-origin pandemic influenza H1N1 virus (S-OIV) when carrying the

142 rom immunocompromised patients infected with pandemic influenza H1N1 were tested for viral fitness, p

143 Here we sequenced 153 pandemic influenza H1N1/09 virus genomes from United Kin

144 of individuals hospitalized with seasonal or pandemic influenza H1N1/09 viruses.

145 H1N1 pandemic influenza has been severe in children.

146 Pandemic influenza in 1918-19 killed more people than di

147 ients hospitalized with laboratory-confirmed pandemic influenza in 9 Influenza Hospitalization Survei

148 effective strategy for slowing the spread of pandemic influenza in countries with social contact netw

149 ern of infection during the epidemic of 2009 pandemic influenza in England is investigated here throu

150 In conclusion, the protracted spread of pandemic influenza in fall 2009 in the US was dominated

151 the geographic and temporal distribution of pandemic influenza in Kenya.

152 n of the first and second waves of 2009-2010 pandemic influenza in South Africa.

153 States; and 3) predict that a third wave of pandemic influenza in the winter or spring of 2010 was u

154 -protective antibodies against the 2009 H1N1 pandemic influenza, indicating antigenic similarities am

155 Seasonal and pandemic influenza infection remains a major public heal

156 Relapses did not follow pandemic influenza infection.

157 as a risk factor for developing severe 2009 pandemic influenza infection.

158 Seasonal and pandemic influenza is a cause of morbidity and mortality

159 Pandemic influenza is a major public health concern, but

160 A key question in pandemic influenza is the relative roles of innate immun

161 tion of factors that drives the emergence of pandemic influenza is unclear, making it impossible to f

162 the morbidity and mortality associated with pandemic influenza isolates.

163 to better predict the impact of epidemic or pandemic influenza mitigation strategies.

164 important strategies to reduce the spread of pandemic influenza need public participation.

165 In the setting of limited resources, like in pandemic influenza, or with the potential limiting of re

166 HIV/AIDS, severe acute respiratory syndrome, pandemic influenza--originate in animals, are caused by

167 this generation and, potentially, since the pandemic influenza outbreak of 1918.

168 preparation is underway to mitigate the next pandemic influenza outbreak.

169 These findings suggest that the timing of pandemic influenza outbreaks is controlled by a combinat

170 y, are consistent with the general timing of pandemic influenza outbreaks observed for 2009 A/H1N1 in

171 In addition to causing the pandemic influenza outbreaks of 1918 and 2009, subtype H

172 Seasonal and pandemic influenza outbreaks remain a major human health

173 A virus (IAV) infections cause seasonal and pandemic influenza outbreaks, which pose a devastating g

174 rains can be transmitted to humans and cause pandemic influenza outbreaks.

175 rotect against infection during seasonal and pandemic influenza outbreaks.

176 swabs, we tracked the course of seasonal and pandemic influenza over five successive cohorts (England

177 ine candidate expressing NA (PIV5-NA) from a pandemic influenza (pdmH1N1) virus or highly pathogenic

178 of NPIs during fall 2009 in response to H1N1 pandemic influenza (pH1N1) by New York City (NYC) public

179 Seasonal and especially pandemic influenza predispose patients to secondary bact

180 his Perspective focuses on the future of the Pandemic Influenza Preparedness (PIP) Framework, which w

181 International Health Regulations (2005), and Pandemic Influenza Preparedness Framework-strives for a

182 za pandemics to direct targeted research and pandemic influenza preparedness planning, emphasizing pr

183 finding could have important implications on pandemic influenza preparedness strategies.

184 t vaccination approach in young children for pandemic influenza preparedness.

185 been the focus of considerable investment in pandemic influenza preparedness.

186 erosol, which again heightens concerns about pandemic influenza preparedness.

187 The Pandemic Influenza Primary Care Reporting (PIPeR) cohort

188 ed in inter-pandemic seasons, the drivers of pandemic influenza remain debated.

189 Seasonal and pandemic influenza remains a constant threat.

190 Circulating levels of both seasonal and pandemic influenza require constant surveillance to ensu

191 potential from sequence data could transform pandemic influenza risk assessment capabilities.

192 te the fair sharing of public health-related pandemic influenza samples between countries.

193 ssion model to simulate a "mild-to-moderate" pandemic influenza scenario to estimate resource needs,

194 Protecting young children from pandemic influenza should also reduce transmission to su

195 In 1918-1919, pandemic influenza spread globally and caused an estimat

196 , but the threat from the emergence of a new pandemic influenza strain might have potentially even mo

197 er potential mutations may generate a future pandemic influenza strain that is oseltamivir-resistant,

198 be immediately mobilized upon infection with pandemic influenza strains derived from antigenic shift.

199 nimal reservoir can lead to the emergence of pandemic influenza strains to which there is little pre-

200 will poise most human subjects to respond to pandemic influenza strains with protective immune respon

201 ies that protect against seasonal as well as pandemic influenza strains.

202 za vaccines lack efficacy against drifted or pandemic influenza strains.

203 ntial to better predict the emergence of new pandemic influenza strains.

204 for absolute humidity in the transmission of pandemic influenza, such as 2009 A/H1N1, has yet to be d

205 an population to respond quickly to emerging pandemic influenza threats.

206 paradigms in disease, ranging from cancer to pandemic influenza to Alzheimer's disease.

207 These include the 2009-10 H1N1 pandemic influenza vaccination campaign, renewed attenti

208 uate the risk of foetal loss associated with pandemic influenza vaccination in pregnancy.

209 ion or nonadjuvanted whole-virion monovalent pandemic influenza vaccine and assessed the immunogenici

210 rther evaluated in a clinical trial as an H2 pandemic influenza vaccine candidate.

211 Three reassortant cold-adapted (ca) H2 pandemic influenza vaccine candidates with hemagglutinin

212 The 4-8-fold antigen-sparing adjuvanted pandemic influenza vaccine demonstrated superior and cli

213 e, developing novel adjuvants is crucial for pandemic influenza vaccine development.

214 e thus represents an advance in seasonal and pandemic influenza vaccine development.

215 en who previously received 2 doses of either pandemic influenza vaccine is safe and is immunogenic fo

216 evidence that 2 doses of AS03(B)-adjuvanted pandemic influenza vaccine may be sufficient to maintain

217 ith current technologies, to have sufficient pandemic influenza vaccine ready in time to impact the f

218 uated different formulations of an H1N1 2009 pandemic influenza vaccine that deliver various viral he

219 vaccines, including oral cholera vaccine and pandemic influenza vaccine, have prompted discussion on

220 olepsy associated with a specific adjuvanted pandemic influenza vaccine.

221 As part of an efficacy trial of pandemic influenza vaccines (NCT01051661), RSV epidemiol

222 une responses provoked by H5N1 and 2009 H1N1 pandemic influenza vaccines after a single dose of intra

223 opment of neutralizing antibody responses to pandemic influenza vaccines and suggest that approaches

224 Since live attenuated pandemic influenza vaccines may potentially express a he

225 It is essential to develop candidate pandemic influenza vaccines that are safe and effective

226 es, in stockpiled, emulsion-based adjuvanted pandemic influenza vaccines, and with demonstrated effic

227 Using seasonal and pandemic influenza vaccines, we document profound differ

228 nation inhibition (HI) antibody responses to pandemic influenza vaccines.

229 mmarize obstacles in designing universal and pandemic influenza vaccines.

230 o response to vaccine when evaluating future pandemic influenza vaccines.

231 A/H1N1 2009 pandemic influenza virus (A/H1N1/pdm09) was first identi

232 effectiveness against illness caused by the pandemic influenza virus (A/H1N1pdm09) was -52.1% (95% C

233 aminidase (NA) antibody titers to 2009(H1N1) pandemic influenza virus (pH1N1) correlated with titers

234 The 2009 pandemic influenza virus (pH1N1) is a swine-origin reass

235 influenza A viruses, which includes the 2009 pandemic influenza virus A/H1N1/2009, highly pathogenic

236 E227A in the hemagglutinin (HA) of the 2009 pandemic influenza virus alter its pathogenesis and tran

237 Although most people infected with the 2009 pandemic influenza virus had mild or unapparent symptoms

238 weakened cytokine responses to the 2009 H1N1 pandemic influenza virus in human cells.

239 demiological patterns of successive waves of pandemic influenza virus in humans has been documented t

240 n these studies, we examined the severity of pandemic influenza virus in obese mice and evaluated ant

241 ortality burden associated with seasonal and pandemic influenza virus infection among pregnant women

242 Pandemic influenza virus infection in pregnancy was asso

243 epigenetic factors on host susceptibility to pandemic influenza virus infection.

244 lung tissues specific to 1918 or 2009 human pandemic influenza virus infections.

245 udy participants challenged with a 2009 H1N1 pandemic influenza virus inoculum containing an A388V po

246 ogenic avian influenza virus (HPAI) and 1918 pandemic influenza virus remain poorly understood.

247 The 2009 H1N1 pandemic influenza virus represents the greatest inciden

248 emergence and rapid spread of the 2009 H1N1 pandemic influenza virus showed that many diagnostic tes

249 errets following intranasal infection with a pandemic influenza virus strain (A/California/4/09 [CA09

250 le with multiple gene segments from the 2009 pandemic influenza virus strain without prior adaptation

251 ction with drifted seasonal as well as novel pandemic influenza virus strains therefore obviating the

252 H5N1 avian, H1N1 seasonal, and H1N1 2009 pandemic influenza virus strains were compared by infect

253 dly reactive and can neutralize seasonal and pandemic influenza virus strains.

254 , and recognize determinants in seasonal and pandemic influenza virus strains.

255 and can be easily upscaled in response to a pandemic influenza virus threat.

256 influenza vaccines that can control emerging pandemic influenza virus threats without the need to gen

257 The rapid dissemination of the 2009 pandemic influenza virus underscores the need for univer

258 We conclude that live attenuated pandemic influenza virus vaccines replicate similarly in

259 idates for development as live attenuated H2 pandemic influenza virus vaccines.

260 The 1918 pandemic influenza virus was the most devastating infect

261 rotein might have in the context of the 2009 pandemic influenza virus, A/California/04/2009 (Cal/09).

262 HA protein is central to the emergence of a pandemic influenza virus, its required molecular propert

263 differ only a few amino acids from the 1918 pandemic influenza virus, suggesting that 1918-like pand

264 rix (M) gene from the Influenza A(H1N1)pdm09 pandemic influenza virus.

265 with great potential for the emergence of a pandemic influenza virus.

266 igenically similar to the swine lineage 2009 pandemic influenza virus.

267 ) infected with the fully reconstructed 1918 pandemic influenza virus.

268 ertain individuals infected with the emerged pandemic influenza virus.

269 enza virus sharing high homology to the 1918 pandemic influenza virus.

270 CC antibodies may enhance protection against pandemic influenza virus.

271 s a major virulence determinant for the 1918 pandemic influenza virus; however, it encodes no known v

272 tween prior exposures to seasonal and recent pandemic influenza viruses and the development of hetero

273 creased genetic sequencing of African A/H1N1 pandemic influenza viruses during 2009-2013 revealed mul

274 Pandemic influenza viruses have consistently higher atta

275 After the emergence of pandemic influenza viruses in 1957, 1968, and 2009, exis

276 nants of the host range and pathogenicity of pandemic influenza viruses in mammals.

277 bute to the optimal competitive advantage of pandemic influenza viruses in mice.

278 que antivirals for treatment of seasonal and pandemic influenza viruses is warranted.

279 Pandemic influenza viruses modulate proinflammatory resp

280 ation today, and in particular, seasonal and pandemic influenza viruses pose a persistent threat to p

281 The emergence of pandemic influenza viruses poses a major public health t

282 In addition to seasonal infections, emerging pandemic influenza viruses present a continued threat to

283 These results show how pandemic influenza viruses subvert the immune response.

284 through antigenic drift and the emergence of pandemic influenza viruses through antigenic shift is un

285 ors of virulence linked to highly pathogenic pandemic influenza viruses without amplification or labe

286 disease in swine infected with seasonal and pandemic influenza viruses, and leads to the suggestion

287 tiviral resistance emergence in seasonal and pandemic influenza viruses, especially in seriously ill

288 virulence, and pathogenic properties of past pandemic influenza viruses, including the 1918 virus, is

289 ctly chart the evolutionary history of human pandemic influenza viruses, which originated in animal h

290 surface protein, which is a key component of pandemic influenza viruses.

291 ith increased virulence in highly pathogenic pandemic influenza viruses.

292 uperior protective adaptive immunity against pandemic influenza viruses.

293 r understanding the origins and evolution of pandemic influenza viruses.

294 rotecting against existing or newly emerging pandemic influenza viruses.

295 -reactive T cells provide protection against pandemic influenza viruses.

296 into viral fitness and the emergence of new pandemic influenza viruses.

297 stering 2 separate vaccines for seasonal and pandemic influenza was necessary in 2009.

298 s matched geographical patterns for the fall pandemic influenza wave.

299 rnel), and a natural history consistent with pandemic influenza; we show that local cumulative incide

300 ssociated with those gaps, for responding to pandemic influenza within and between six territories in